bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Supportive Therapy

Hydration

  • Maintain adequate hydration to prevent excessive mucus viscosity

Nutritional Programs

  • There are no direct or measurable effects on lung function in treating malnutrition but subjective relief and objective improvement in strength and exercise performance do occur
    • Dietary supplementation should be considered if patient is malnourished (body weight <85% of ideal) or experiencing early satiety
  • Advise patient to obtain nutritional counseling to reduce weight if obese

Oxygen Therapy

  • Cornerstone of COPD exacerbation treatment
  • Low-flow O2 should be administered if hypoxemia is present
  • Excess use of O2 should be avoided as this may lead to progressive hypercapnia, either by decreasing hypoxic ventilatory drive or by worsening ventilation-perfusion mismatching within the lung
  • Once O2 therapy is initiated, arterial blood gas should be monitored 30-60 minutes later to ensure satisfactory oxygenation without acidosis or CO2 retention
  • Goal of supplemental O2 therapy should be arterial oxygen partial pressure at or just above 60 mmHg

Noninvasive Positive Pressure Ventilation

  • Frequently used for inpatient management of AECB patients who are significantly hypoxemic or with a serum pH <7.3
  • Improves ventilation and lower pCO2 levels and may be a means of avoiding intubation
  • Decreases hospital or intensive care unit length of stay and morbidity
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.